Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Natera, Inc.
< Previous
1
2
Next >
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
September 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
September 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
June 17, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
May 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its First Quarter 2024 Results on May 9
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
April 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit